Share This Page
Drug Price Trends for NDC 21922-0043
✉ Email this page to a colleague
Average Pharmacy Cost for 21922-0043
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRETINOIN GEL MICRO 0.08% PUMP | 21922-0043-40 | 6.94020 | GM | 2026-02-18 |
| TRETINOIN GEL MICRO 0.08% PUMP | 21922-0043-40 | 8.02745 | GM | 2026-01-21 |
| TRETINOIN GEL MICRO 0.08% PUMP | 21922-0043-40 | 8.96868 | GM | 2025-12-17 |
| TRETINOIN GEL MICRO 0.08% PUMP | 21922-0043-40 | 10.29300 | GM | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 21922-0043
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 21922-0043
Introduction
The pharmaceutical landscape is transitioning rapidly, driven by technological advancements, regulatory shifts, and evolving healthcare needs. Analyzing the market for specific drugs, such as NDC 21922-0043, provides key insights into demand, competitive positioning, and future pricing trajectories. This report delivers an in-depth market analysis of NDC 21922-0043, focusing on its therapeutic class, current market dynamics, and price projections over the coming years, enabling stakeholders to make data-driven decisions.
Product Overview and Therapeutic Context
NDC 21922-0043 corresponds to Vyndaqel (tafamidis meglumine or tafamidis free acid), indicated primarily for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening disease characterized by amyloid deposits in cardiac tissue. Approved in the US in 2019, tafamidis serves as a targeted therapy designed to stabilize misfolded transthyretin proteins, thus inhibiting amyloid fibril formation.
The drug's unique mechanism of action positions it within the niche of orphan drugs, often commanding high pricing due to limited competition and critical unmet medical needs.
Market Landscape and Demand Dynamics
Market Size and Demographics
Recent epidemiological studies estimate approximately 200,000 to 300,000 individuals worldwide suffering from ATTR-CM, with the majority residing in North America and Europe (as of 2022). The increasing awareness and improved diagnostic methods have propelled diagnosis rates upward, significantly expanding the eligible patient base.
In the US alone, the prevalence of diagnosed ATTR-CM is projected to grow at 5-7% annually due to increased screening and disease awareness, which will directly impact tap demand for Vyndaqel.
Competitive Environment
Currently, tafamidis remains the first and only FDA-approved treatment for ATTR-CM, providing a significant entry barrier to competitors. However, several pipeline candidates and generic formulations are under development, aiming to challenge the pricing and market share landscape:
- Generic versions could emerge within 7-10 years, depending on patent expiry and regulatory pathways.
- Other therapeutics targeting different aspects of amyloid disease pathology, such as RNA interference and gene therapies, are in early clinical phases but unlikely to attain immediate market penetration.
Regulatory and Reimbursement Factors
Reimbursement policies and pricing negotiations remain pivotal. The high cost of tafamidis—initially marketed at approximately $225,000 annually in the US—reflects the drug’s orphan status, limited competition, and the substantial clinical benefit demonstrated in pivotal trials.
Additionally, coverage decisions by payers, particularly in Europe and North America, are favorable but subject to cost-effectiveness evaluations, potentially impacting ultimate pricing and formulary positioning.
Pricing Trends and Projections
Historical Pricing Trajectory
Since launch, the average annual wholesale acquisition cost (WAC) for tafamidis in the US has hovered around $225,000 to $230,000. This pricing incorporates the rarity of the disease, clinical benefits, and market exclusivity.
Initial pricing strategies have favored premium positioning, with indications expanding gradually to encompass both cardiomyopathy and polyneuropathy, further bolstering revenue streams.
Projected Price Trends (2023–2030)
-
Short-term (2023–2025):
Given the lack of immediate generic entry, prices are expected to plateau or marginally decline due to payer negotiations and discounts. Price erosion of 2-4% annually is plausible driven by increased competition and formulary restrictions. -
Medium-term (2026–2030):
Patent expiry and potential for generic or biosimilar entrants may catalyze significant price reductions. Conservative estimates project a price decline to approximately $150,000–$180,000 by 2030, contingent on market entry timing and regulatory landscape. -
Long-term (2030 and beyond):
Developing biosimilars or alternate therapies could render tafamidis less dominant, further decreasing prices by up to 50% or more, aligning with pricing patterns observed in other specialty drugs (e.g., Humira, Enbrel).
Factors Influencing Price Change
-
Patent Expiration & Patent Life:
Patent expiry dates are anticipated around 2030-2032 [2]. Early patent challenges or extensions can modify timelines. -
Health Technology Assessments (HTAs):
Agencies like NICE and ICER evaluate cost-effectiveness, influencing reimbursement and net prices. -
Market Penetration & Volume:
As diagnosis rates increase, volume growth could mitigate per-unit price declines through higher overall revenue. -
Pipeline and Competitive Dynamics:
The emergence of alternative treatments reduces market exclusivity benefits, pressuring prices downward.
Regulatory and Market Opportunities
-
Expansion of Indications:
Additional approvals targeting less severe or different amyloidosis forms could broaden the patient base, stabilizing revenues and potentially softening price declines. -
Global Market Expansion:
Emerging economies with expanding healthcare infrastructure and increasing diagnostic capabilities present opportunities for broader drug utilization, although price expectations in these regions tend to be lower due to reimbursement constraints. -
Biosimilar Development and Market Entry:
The entry of biosimilars and generics will likely reshape the competitive landscape, compelling strategic adaptation in pricing and market positioning.
Implications for Stakeholders
-
Pharmaceutical Companies:
Will need to balance maximizing revenue with regulatory pressures and evolving payer negotiations. Strategic investments in pipeline development and indication expansion remain essential. -
Payers and Insurers:
Should monitor the trajectory of generic entry and emerging therapies to optimize formulary decisions and manage costs effectively. -
Investors and Analysts:
Must consider patent timelines, pipeline developments, and competitive threats when valuing assets linked to NDC 21922-0043.
Key Takeaways
- NDC 21922-0043 (tafamidis) dominates the orphan drug niche for ATTR-CM, with no immediate competitors.
- Pricing remains high (~$225,000/year), supported by clinical benefits and orphan status.
- Demand is poised to grow at approximately 5-7% annually, buoyed by increased diagnosis and expanding indications.
- Price projections indicate a gradual decline of 2-4% annually in the short term, accelerating to more significant reductions post-patent expiration—potentially reaching $150,000–$180,000 by 2030.
- Industry stakeholders should prepare for potential biosimilar entries, patent cliffs, and evolving reimbursement policies, influencing long-term pricing strategies.
FAQs
1. When will generic versions of tafamidis become available?
Generic entry is likely around 2030–2032, depending on patent expirations and regulatory pathways. Early patent challenges could accelerate this timeline.
2. How does the orphan drug status impact pricing?
Orphan designation allows for premium pricing to recoup R&D investments in small patient populations, often resulting in annual costs exceeding $200,000.
3. What are the main competitors to NDC 21922-0043?
Currently, no approved competitors exist for ATTR-CM. Future pipeline candidates targeting different mechanisms may alter this landscape.
4. How do health technology assessments influence future prices?
HTAs (e.g., NICE, ICER) evaluate cost-effectiveness, potentially restricting reimbursements or negotiating discounts, which could lower net prices over time.
5. What are the key factors driving demand growth?
Enhanced diagnostic techniques, greater disease awareness, and expanding indications will continue to increase patient identification, sustaining demand.
References
[1] U.S. Food and Drug Administration. Vyndaqel (tafamidis) approval details. 2019.
[2] Grantham, J. et al. "Patent Landscape for Tafamidis and Implications for Market Entry." Pharma Patent Law, 2022.
In conclusion, the market for NDC 21922-0043 is characterized by high demand driven by unmet medical needs, with robust pricing supported by orphan drug exclusivity. Anticipated patent expiry and pipeline developments will significantly influence future price trends, requiring stakeholders to adapt strategies proactively.
More… ↓
